Table 3 The characteristics of the training, temporal validation and external validation cohorts
Variables | Training cohort (n = 592) | Temporal validation cohort (n = 196) | External validation cohort (n = 65) |
|---|---|---|---|
Age(years) | 61.84 ± 14.16 | 61.58 ± 13.42 | 67.02 ± 16.89 |
Male sex, n(%) | 281(47.5) | 102(52.0) | 31(47.7) |
Charlson comorbidity index | 6.81 ± 1.58 | 7.21 ± 1.47 | 7.17 ± 1.86 |
Cognitive dysfunction, n(%) | 58(9.8) | 11(5.6) | 7(10.8) |
Barthel Index, n(%) | Â | Â | Â |
 61–100 | 197(33.3) | 39(19.9) | 10(15.4) |
 41–60 | 130(22.0) | 49(25.0) | 17(26.1) |
 ≤ 40 | 265(44.7) | 108(55.1) | 38(58.5) |
Sodium, n(%) | Â | Â | Â |
 ≥ 136 mmol/L | 474(80.1) | 153(78.1) | 25(38.5) |
 125–136 mmol/L | 84(14.2) | 27(13.8) | 36(55.4) |
 < 125 mmol/L | 34(5.7) | 16(8.1) | 4(6.1) |
TBIL, n(%) | Â | Â | Â |
 < 34.2 umol/L | 216(36.5) | 87(44.4) | 56(86.2) |
 34.2–171 umol/L | 314(53.0) | 93(47.4) | 6(9.2) |
 ≥ 171 umol/L | 62(10.5) | 16(8.2) | 3(4.6) |
OME, n(%) | Â | Â | Â |
 0 | 143(24.2) | 49(25.0) | 19(29.2) |
 ≤ 30 mg/d | 256(43.2) | 84(42.9) | 29(44.6) |
 30–90 mg/d | 102(17.2) | 30(15.3) | 10(15.4) |
 > 90 mg/d | 91(15.4) | 33(16.8) | 7(10.8) |
Anticholinergic use, n(%) | 365(61.7) | 113(57.7) | 45(69.2) |
Delirium, n(%) | 188(31.8) | 69(35.2) | 28(43.1) |